As there are no randomized trials for MPNST to justify this treatment, recommendations are based on data from the high grade soft tissue sarcoma group as a whole, including both sporadic and NF1-associated MPNST [4,5,6]. Here, NF1 is linked to malignant peripheral nerve sheath tumor.